Immunomodulatory progenitor cell therapy - Celixir

Drug Profile

Immunomodulatory progenitor cell therapy - Celixir

Alternative Names: Heartcel; iMP cell therapy - Celixir; iMP-cells

Latest Information Update: 11 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cell Therapy Limited
  • Developer Celixir
  • Class Cardiovascular therapies; Cell therapies; Stem cell therapies
  • Mechanism of Action CD antigen modulators; CD45 antigen modulators; Cell replacements; Epidermal growth factor receptor modulators; Immunomodulators; Major histocompatibility complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Cardiomyopathies
  • Phase II Heart failure

Most Recent Events

  • 08 Jun 2018 US FDA approves IND application for iMP cell therapy ( HeartcelTM) in Heart failure
  • 12 Jan 2018 Celixir plans a phase IIb trial for Heart failure in United Kingdom
  • 08 Jan 2018 The Medicines and Healthcare Products Regulatory Agency approves a clinical trial application for a phase IIb trial of Immunomodulatory progenitor cell therapy in Heart failure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top